Oct 2026· Clinical and Translational Oncology· 0 citations· 26 references
Medicine
TL;DR
Real-world evidence is provided of the molecular and clinical heterogeneity of EGFR exon 20-altered NSCLC and a possible survival difference according to loop location and a potentially favorable association between sunvozertinib exposure and OS among non-surgical patients are highlighted.
EGFR mutation testing is essential for therapeutic decision-making in non–small cell lung cancer (NSCLC). Routine assays primarily detect common EGFR alterations, such as exon 19 deletions and L858R substitutions, but may fail to identify rare or non-classical variants. At National Taiwan University Hospital (NTU...
Background Rare epidermal growth factor receptor (EGFR) mutations are heterogeneous, and their significance after complete resection of stage I lung adenocarcinoma (LUAD) remains unclear. We evaluated the mutation spectrum, clinicopathological correlates, postoperative recurrence patterns, and survival outcomes of a st...
La-Jie Man, Liang Xia, Chuan Li et al.· Translational Lung Cancer Re...· 0 citations
703
Background:
Epidermal growth factor receptor mutations (EGFRm) occur in ~15% of non-small cell lung cancer (NSCLC) cases, with exon 19 deletions (Ex19del) and exon 21 L858R substitutions (L858R) comprising 85-90%. Osimertinib (Osi) monotherapy (mono) is one of the first-line (1L) treatment options, while mo...
S. Gruber, P. Vadagam, L. Morrison et al.· JCO Oncology Practice· 0 citations
Background and Objective Epidermal growth factor receptor exon 20 insertion mutations (EGFR ex20ins) define a rare, structurally heterogeneous subtype of non-small cell lung cancer (NSCLC) that is relatively insensitive to conventional EGFR tyrosine kinase inhibitors. Although amivantamab, sunvozertinib, zipalertinib,...
Zhuo-Ran Li, Yi-Chao Han, Wen-Zhao Zhong et al.· Translational Lung Cancer Re...· 0 citations
Objectives: Precision medicine has improved outcomes in advanced lung cancer, but its implementation remains limited. The prospective LANTERN project (NCT05802771) involves comprehensive clinical and multi-omics data collection. Here, we report preliminary genomic findings, focusing on the prognostic impact of gene mut...
C. Sassorossi, E. De Paolis, Jessica Evangelista et al.· Genes· 0 citations
BACKGROUND
Uncommon and complex EGFR variants respond variably to tyrosine kinase inhibitors, and data on their frequency in Brazil are scarce.
METHODS
We retrospectively analysed 141 patients with EGFR-mutated lung adenocarcinoma at a single Northeastern Brazilian centre. All profiling used treatment-naive diagnosti...
J. C. de Sousa, Cleto Nogueira, Guilherme de Sousa Veloso et al.· Cancer Treatment and Researc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
